Progress towards clinically useful aldosterone synthase inhibitors.

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Pharmacology

Background:

• Aldosterone synthase (CYP11B2) and cortisol synthase (CYP11B1) share high structural similarity, complicating selective inhibitor design.
• Existing therapies targeting the renin-angiotensin-aldosterone system demonstrate significant clinical benefits.

Purpose of the Study:

• To develop highly selective inhibitors for CYP11B2 and CYP11B1.
• To explore the therapeutic potential of aldosterone synthase inhibitors (ASis).

Main Methods:

• Novel enzyme screening assays were developed.
• Extensive medicinal chemistry efforts were employed.
• Selectivity profiling against other cytochrome P450 enzymes was performed.

Main Results:

• Potent CYP11B2 inhibitors with up to 1000-fold selectivity over CYP11B1 were identified.
• Inhibitors also demonstrated selectivity against other steroidogenic and hepatic P450 enzymes.
• CYP11B1 inhibitors with up to 50-fold selectivity were discovered, though less explored.

Conclusions:

• Significant progress has been made in developing selective CYP11B2 inhibitors.
• Emerging data from preclinical and clinical studies suggest therapeutic promise for ASis.
• Further challenges remain in the development of clinically useful ASis.